Research programme: vascular targeting agents - JOMED/OXiGENE
Alternative Names: Vascular targeting agents - JOMED/OXiGENELatest Information Update: 26 Apr 2007
At a glance
- Originator JOMED; OXiGENE
- Developer JOMED
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery restenosis; Vascular restenosis
Most Recent Events
- 26 Apr 2007 Discontinued - Preclinical for Coronary artery restenosis in Europe (Implant)
- 26 Apr 2007 Discontinued - Preclinical for Vascular restenosis in Europe (Implant)
- 05 Aug 2002 Preclinical trials in Coronary artery restenosis in Europe (Implant)